Make a Difference

The Promise Campaign will expand our care to more children, and offer comfort to the people who love them.

Health Conditions

The Epilepsy Center at Texas Children’s Hospital evaluates and treats children with seizure disorders and epilepsy. The center offers comprehensive care for children with epilepsy and seizures that includes:

  • Treatment with antiepileptic medications (current and investigational)
  • The ketogenic diet and related diets
  • Vagus nerve stimulation
  • State-of-the-art resective surgical procedures
  • MRI-guided laser ablation surgery

The center's multidisciplinary team includes pediatric epileptologists, neurosurgeons, specialized pediatric nurse practitioners, neuropsychologists, neuroradiologists, neuropathologists, dietitians and a social worker. 

National Association of Epilepsy CentersIn addition, Texas Children's Epilepsy Center is recognized by the National Association of Epilepsy Centers (NAEC) as a Level 4 epilepsy center. Level 4 epilepsy centers have the professional expertise and facilities to provide the highest level medical and surgical evaluation and treatment for patients with complex epilepsy.

Our physician-scientists and basic researchers at the Gordon and Mary Cain Pediatric Neurology Research Foundation Laboratory conduct cutting-edge research to identify underlying molecular causes and potential therapies for devastating childhood catastrophic epilepsies.

In 2010, extensive preclinical cellular and animal studies by Cain lab researchers culminated in the identification of a rapamycin analog, everolimus, as a potential therapy against severe epilepsy due to brain malformations in Tuberous Sclerosis Complex. In a small FDA-approved clinical trial conducted at the Texas Children’s and Cincinnati Children’s Hospitals, it was demonstrated that most of the severely epileptic children treated with everolimus had significantly fewer seizures.  Encouraged by those positive results, a much larger international clinical trial was undertaken and successfully completed in 2016. Texas Children’s Hospital and Baylor College of Medicine were major sites for this trial. This promising large trial confirmed that everolimus may be a therapeutic option for refractory epilepsy in TSC patients.